ETOPOSIDE(E) + EPIRUBICIN(E) + CISPLATIN(P) COMBINATION CHEMOTHERAPY (EEP) IN ADVANCED GASTRIC-CANCER - NEGATIVE IMPACT ON CLINICAL OUTCOME

被引：16

作者：

DIAZRUBIO, E

JIMENO, J

ARANDA, E

MASSUTI, B

CAMPS, C

CERVANTES, A

DORTA, J

HERNANDEZ, JJC

DOMINGUEZ, S

ANTON, A

CARRATO, A

VILLAR, A

MACHENG, I

ALONSON, JD

MARTOS, CF

GONZALEZ, R

FONSECA, E

BALANA, C

HERNANDEZ, JJS

机构：

来源：

ANNALS OF ONCOLOGY | 1992年 / 3卷 / 10期

关键词：

ADVANCED GASTRIC CANCER; EEP COMBINATION CHEMOTHERAPY;

D O I：

10.1093/oxfordjournals.annonc.a058113

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

One hundred nineteen patients with advanced gastric cancer were included in a study comparing EEP vs. FEM chemotherapy. The response rate was higher (30%) in patients on EEP than in those treated with FEM (p=0.05). Severe leukopenia, anemia, alopecia and infection were significantly more frequent on EEP. In addition, because of its intrinsic toxicity, EEP chemotherapy has a negative impact on the performance status of patients treated with this regimen, more than half of whom presented at least one episode of severe symptomatic toxcity while on EEP chemotherapy. The median time to progression and median survival for EEP-FEM were 2.08-3.4 and 4.2-7.9 months, respectively. Our data do not support the use of EEP chemotherapy in patients with AGC.

引用

页码：861 / 863

页数：3

共 15 条

[1] MMAF FOR ADVANCED GASTRIC-CANCER [J].

ANDERSON, H ;

SCARFFE, JH ;

RANSON, M ;

KAMTHAN, AG ;

DOUGAL, M ;

RUSSELL, SA ;

WILKINSON, MJS ;

OSTICK, DG .

EUROPEAN JOURNAL OF CANCER, 1991, 27 (10) :1234-1238

[2]

BALANA C, 1990, ANN ONCOL S, V1, P45

[3] FAMTX VERSUS ETOPOSIDE, DOXORUBICIN, AND CISPLATIN - A RANDOM ASSIGNMENT TRIAL IN GASTRIC-CANCER [J].

KELSEN, D ;

ATIQ, OT ;

SALTZ, L ;

NIEDZWIECKI, D ;

GINN, D ;

CHAPMAN, D ;

HEELAN, R ;

LIGHTDALE, C ;

VINCIGUERRA, V ;

BRENNAN, M .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :541-548

[4] ETOPOSIDE, DOXORUBICIN, AND CISPLATIN CHEMOTHERAPY FOR ADVANCED GASTRIC ADENOCARCINOMA - RESULTS OF A PHASE-II TRIAL [J].

LERNER, A ;

GONIN, R ;

STEELE, GD ;

MAYER, RJ .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :536-540

[5] 5-FLUOROURACIL, DOXORUBICIN, AND MITOMYCIN (FAM) COMBINATION CHEMOTHERAPY FOR ADVANCED GASTRIC-CANCER [J].

MACDONALD, JS ;

SCHEIN, PS ;

WOOLLEY, PV ;

SMYTHE, T ;

UENO, W ;

HOTH, D ;

SMITH, F ;

BOIRON, M ;

GISSELBRECHT, C ;

BRUNET, R ;

LAGARDE, C .

ANNALS OF INTERNAL MEDICINE, 1980, 93 (04) :533-536

[6]

MANSI JL, 1990, ANN ONCOL S, V1, P44

[7]

MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO

[8]

2-6

[9] PHASE-II STUDY WITH THE COMBINATION ETOPOSIDE, DOXORUBICIN, AND CISPLATIN IN ADVANCED MEASURABLE GASTRIC-CANCER [J].

PREUSSER, P ;

WILKE, H ;

ACHTERRATH, W ;

FINK, U ;

LENAZ, L ;

HEINICKE, A ;

MEYER, J ;

MEYER, HJ ;

BUENTE, H .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (09) :1310-1317

[10] PHASE-II TRIAL OF ETOPOSIDE, DOXORUBICIN (ADRIAMYCIN), AND CISPLATIN (EAP REGIMEN) IN ADVANCED GASTRIC-CANCER [J].

SPARANO, JA ;

SCHWARTZ, EL ;

SALVA, KM ;

PIZZILLO, MF ;

WADLER, S ;

WIERNIK, PH .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (05) :374-378

← 1 2 →